The therapeutic effects of a high velocity resistance training intervention for chemotherapy induced polyneuropathy

Abstract

Chemotherapy induced polyneuropathy, also referred to as chemotherapy induced peripheral neuropathy (CIPN) is a dose dependent, neurotoxicity from known neuropathic agents, such as taxanes, platinums, and vinca alkaloids, causing damage to the peripheral nervous system which sends signals between the central nervous system and the body. CIPN can present as sensory, motor, or autonomic symptoms, such as paresthesia, hyperpathia, hypoesthesia, muscle weakness, balance impairments, orthostatic hypotension, or altered sexual function. Currently, there are no standard treatment or standard prevention methods for CIPN. The purpose of this case series was to assess the therapeutic effects of a high velocity resistance training (HVRT), or power training, in women diagnosed and treated for cancer, who presented with CIPN by measuring balance, functional performance, neuropathy, quality of life (QoL), and an inflammatory biomarker (c-reactive protein [CRP]). The HVRT consisted of 24 exercise sessions over 12 weeks including upper and lower extremity movements. The intensity prescribed was 30-60% one repetition maximum for upper extremity, and 0-60% one repetition maximum for lower extremity exercises. Findings demonstrate the feasibility of designing and implementing a HVRT intervention to potentially attenuate CIPN symptoms. Moreover, HVRT may improve in balance, functional performance, and QoL outcomes. Although the CRP results increased, the values remained within normal limits (Quest Diagnostics, n.d.), thus lifestyle modifications are needed. This study provides encouraging evidence for a future HVRT intervention pilot study modulating CIPN symptoms. Assessments such as balance, functional performance, and inflammatory markers should be measured prior and throughout treatment in persons receiving known neuropathic agents to better establish baseline values. Further research is needed to enable clinicians to provide comprehensive and effective treatment plans for persons with neuropathy, subsequently improving QoL